From nanoparticles to cancer nanomedicine: Old problems with new solutions

Chi Ling Chiang, Ming Huei Cheng, Chih Hsin Lin

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. Despite abundant options of anticancer drugs, it remains challenging to have agents specifically target cancer cells while reducing collateral toxicity to healthy tissue. Nanocompartments that can be selective toward points deeply within malignant tissues are a promising concept, but the heterogeneity of tumor tissue, inefficiency of cargo loading and releasing, and low uniformity of manufacture required from preclinical to commercialization are major obstacles. Technological advances have been made in this field, creating engineered nanomaterials with improved uniformity, flexibility of cargo loading, diversity of surface modification, and less inducible immune responses. This review highlights the developmental process of approved nanomedicines and the opportunities for novel materials that combine insights of tumors and nanotechnology to develop a more effective nanomedicine for cancer patients.

Original languageEnglish
Article number1727
Issue number7
Publication statusPublished - Jul 2021


  • Nanomaterials
  • Nanomedicines
  • Nanoparticles
  • Nanotechnology

ASJC Scopus subject areas

  • Chemical Engineering(all)
  • Materials Science(all)


Dive into the research topics of 'From nanoparticles to cancer nanomedicine: Old problems with new solutions'. Together they form a unique fingerprint.

Cite this